Actelion's Founders Start New Biotech, With J&J's Backing
Mar 2, 2017 - The Wall Street Journal
Jean-Paul and Martine Clozel, founders of Swiss biotech company Actelion, which has been sold to J&J, are starting over again. The husband and wife team is embarking on the creation of a new global biotech player—armed with nearly $1 billion in capital, a deep-pocketed partner in J&J and soon, a stock listing in Zurich. Read More
Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox